Table 1 Baseline characteristics.
Characteristic n (%) / Median (range) | Patients (N = 17) |
|---|---|
Median age, years | 39 (20–51) |
Sex | |
 Male | 9 (52.9) |
 Female | 8 (47.1) |
Median time since diagnosis, months | 17 (4–28) |
ECOG performance status before ssCART-19 infusion | |
 0 | 5 (29.4) |
 1 | 12 (70.6) |
Philadelphia positive | |
 Yes | 3 (17.6) |
 No | 14 (82.4) |
Previous TKI therapy | |
 Yes | 4 (23.5) |
 No | 13 (76.5) |
Previous stem cell transplantation | |
 Auto-HSCT | 0 (0.0) |
 Allo-HSCT | 2 (11.8) |
 No | 15 (88.2) |
Disease status | |
 Refractory | 3 (17.6) |
 Relapsed | 14 (82.4) |
Number of relapses | |
 0 | 3 (17.6) |
 1 | 10 (58.9) |
 2 | 2 (11.8) |
 >2 | 2 (11.8) |
Previous bridging therapy | |
 Yes | 14 (82.4) |
 No | 3 (17.6) |
High-risk cytogenetic features | |
 Yes | 8 (47.1) |
 No | 9 (52.9) |
Bone marrow leukemia blasts at screening | |
 ≤5% | 0 (0.0) |
 >5%, ≤25% | 8 (47.1) |
 >25%, ≤50% | 1 (5.9) |
 >50%, ≤75% | 4 (23.5) |
 >75% | 4 (23.5) |
Extramedullary disease at screening | |
 Yes | 1 (5.9) |
 No | 16 (94.1) |
CNSL disease at screening | |
 Yes | 1 (5.9) |
 No | 16 (94.1) |
